CBD Life Sciences Statistics
Total Valuation
CBD Life Sciences has a market cap or net worth of 1.39 million. The enterprise value is 1.46 million.
| Market Cap | 1.39M |
| Enterprise Value | 1.46M |
Important Dates
The last earnings date was Thursday, December 5, 2024.
| Earnings Date | Dec 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CBD Life Sciences has 2.78 billion shares outstanding. The number of shares has increased by 8.24% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.78B |
| Shares Change (YoY) | +8.24% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.38 |
| PB Ratio | 0.26 |
| P/TBV Ratio | 9.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.56 |
| EV / Sales | 8.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16
| Current Ratio | 4.16 |
| Quick Ratio | 3.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.08% and return on invested capital (ROIC) is -28.17%.
| Return on Equity (ROE) | -45.08% |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | -28.17% |
| Revenue Per Employee | 44,612 |
| Profits Per Employee | -26,859 |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.67% in the last 52 weeks. The beta is 52.72, so CBD Life Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 52.72 |
| 52-Week Price Change | +66.67% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 50.27 |
| Average Volume (20 Days) | 32,109,323 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, CBD Life Sciences had revenue of 178,448 and -107,437 in losses. Loss per share was -0.00.
| Revenue | 178,448 |
| Gross Profit | 80,406 |
| Operating Income | -107,437 |
| Pretax Income | -107,437 |
| Net Income | -107,437 |
| EBITDA | -51,880 |
| EBIT | -107,437 |
| Loss Per Share | -0.00 |
Balance Sheet
| Cash & Cash Equivalents | 82 |
| Total Debt | n/a |
| Net Cash | 82 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 342,201 |
| Book Value Per Share | 0.00 |
| Working Capital | 140,714 |
Cash Flow
| Operating Cash Flow | -19,586 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 45.06%, with operating and profit margins of -60.21% and -60.21%.
| Gross Margin | 45.06% |
| Operating Margin | -60.21% |
| Pretax Margin | -60.21% |
| Profit Margin | -60.21% |
| EBITDA Margin | -29.07% |
| EBIT Margin | -60.21% |
| FCF Margin | n/a |
Dividends & Yields
CBD Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.24% |
| Shareholder Yield | -8.24% |
| Earnings Yield | -158.20% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on April 22, 2024. It was a reverse split with a ratio of 0.0033333.
| Last Split Date | Apr 22, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0033333 |
Scores
CBD Life Sciences has an Altman Z-Score of -22.42. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.42 |
| Piotroski F-Score | n/a |